Efficacy and Safety of Once Daily Dosing Compared to Twice Daily Dosing of Nitisinone in HT-1

NCT02323529 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

18

Enrollment

INDUSTRY

Sponsor class

Conditions

Hereditary Tyrosinemia, Type I

Interventions

DRUG: Nitisinone

Sponsor

Swedish Orphan Biovitrum